Table 1a.
Baseline Patient characteristics and outcomes
| Characteristics | Total | IC/HDAC combinations | HMA combinations | CPX | LDAC combinations | INV | P-Value | |
|---|---|---|---|---|---|---|---|---|
| N=931 | N=396 | N=220 | N=20 | N=186 | N=109 | |||
| Patient related characteristics: | ||||||||
| Age at diagnosis | 60–65 yrs (%) | 246 (26) | 148 (37) | 35 (16) | 5 (25) | 40 (22) | 18 (17) | <.001 |
| 65–70 yrs (%) | 325 (35) | 127 (32) | 84 (38) | 7 (35) | 80 (43) | 28 (26) | ||
| ≥70 yrs (%) | 360 (39) | 121 (30) | 101 (46) | 8 (40) | 66 (36) | 63 (58) | ||
| WBC (K/μL) | 3.4 (0.2–433) | 3.9 (0.3–1.9) | 2.7 (0.2–93) | 3.8 (0.7–61) | 3.2 (0.4–433) | 3.8 (0.6–77) | 0.02 | |
| PLT (K/μL) | 41 (1–936) | 41 (2–708) | 41 (1–454) | 33 (9–173) | 41 (5–445) | 47 (5–936) | 0.33 | |
| LDH (IU/L) | 668 (190–13688) | 723 (251–13688) | 603 (190–7585) | 630 (425–2493) | 626 (300–8887) | 670 (322–17486) | 0.01 | |
| Total Bilirubin (mg/dL) | 0.6 (0–2) | 0.6 (0.1–1.7) | 0.6 (0–1.9) | 0.7 (0.3–1) | 0.6 (0.1–1.7) | 0.5 (0.1–1.7) | 0.42 | |
| Creatinine (mg/dL) | 0.9 (0.4–1.9) | 1.0 (0.4–1.9) | 0.9 (0.4–1.9) | 0.8 (0.6–1.7) | 0.9 (0.4–1.9) | 1 (0.5–1.8) | 0.02 | |
| ECOG performance status (PS) | 0–1 | 649 (70) | 279 (70) | 149 (68) | 10 (50) | 148 (80) | 63 (58) | 0.9 |
| 2 | 147(16) | 79 (20) | 34 (15) | 4 (20) | 18 (10) | 12 (11) | ||
| undocumented | 135 (14) | 38 (10) | 37 (17) | 6 (30) | 20 (10) | 44 (31) | ||
| Disease related characteristics: | ||||||||
| Peripheral blood blasts (%) | 9 (0–98) | 91 (0–96) | 8 (0–95) | 5 (0–91) | 8 (0–98) | 10 (0–92) | 0.32 | |
| Bone marrow blasts (%) | 36 (0–96) | 40 (0–95) | 35 (3–89) | 36 (10–83) | 35 (4–96) | 28 (0–89) | 0.004 | |
| Prior therapy for antecedent disorder (%) | 244 (26) | 79 (20) | 35 (16) | 13 (65) | 63 (34) | 54 (49.5) | <.001 | |
| Cytogenetic category (per ELR): | ||||||||
| Adverse (%) | 537 (58) | 238 (60) | 125 (57) | 9 (45) | 116 (62) | 49 (45) | 0.44 | |
| Diploid (%) | 160 (17) | 62 (16) | 43 (20) | 5 (25) | 29 (16) | 20 (18) | ||
| Intermediate (%) | 132 (14) | 54 (14) | 38 (17) | 5 (25) | 23 (12) | 11 (10) | ||
| Unknown (%) | 102 (11) | 42 (11) | 14 (6) | 1 (5) | 16 (9) | 29 (27) | - | |
| Outcomes: | ||||||||
| Complete response [CR/CRp] (%) | 368 (39.5) | 183 (46) | 79 (36) | 9 (45) | 80 (43) | 17 (15.6) | <.001 | |
| Partial response [PR/HI] (%) | 43 (4.5) | 9 (2.2) | 26 (12) | 2 (10) | 6 (3.2) | 0 (0) | ||
| No response [NR] (%) | 335 (36) | 113 (28) | 88 (40) | 7 (35) | 64 (34.5) | 63 (57.8) | ||
| 8- (week mortality [LT-8W] | 185 (19.8) | 91 (22.9) | 27 (12.2) | 2 (10) | 36 (19.3) | 29 (26.6) | - | |
| Overall survival (median in months) | 6 | 5.4 | 6.7 | 7.6 | 7.1 | 4.6 | 0.002 | |